Managers / Q4 2018 · view latest →
Athyrium Capital Management, LP
CIK 0001728001 · 505 FIFTH AVENUE, FLOOR 18, NEW YORK, NY, 10017 · 212-402-6925
Summary
Athyrium Capital Management, LP reported $104M in U.S.-listed holdings across 3 positions for Q4 2018.
The portfolio is heavily concentrated: Aegerion Pharmaceuticals alone accounts for 85.9% of reported value.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- US DOMESTIC · 93.7% · $97M
- Other · 6.3% · $7M
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AEGERION PHARMACEUTICALS INC | NEW | +117.74M | 117.74M | +$89M | $89M |
| PTC THERAPEUTICS INC | NEW | +8.07M | 8.07M | +$8M | $8M |
| KALA PHARMACEUTICALS INC | NEW | +1.33M | 1.33M | +$7M | $7M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2018
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | AEGERION PHARMACEUTICALS INC | NOTE 2.000% 8/1 | 85.94% | $89M | 117.74M |
| 2 | PTC THERAPEUTICS INC | NOTE 3.000% 8/1 | 7.78% | $8M | 8.07M |
| 3 | KALA PHARMACEUTICALS INC | COM | 6.28% | $7M | 1.33M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2024 | $9M | 2 | Nov 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $34M | 3 | Aug 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $73M | 3 | May 16, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $69M | 3 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $114M | 6 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $154M | 7 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $279M | 8 | May 16, 2023 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2022 | $238M | 11 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $267M | 11 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $238M | 11 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $281M | 10 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $280M | 6 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $158M | 5 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $240M | 5 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $198M | 4 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $208M | 3 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $5M | 1 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $9M | 1 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $98M | 2 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $104M | 3 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.